Zhejiang Ausun Pharmaceutical Co Ltd (603229) - Total Assets
Based on the latest financial reports, Zhejiang Ausun Pharmaceutical Co Ltd (603229) holds total assets worth CN¥3.16 Billion CNY (≈ $461.94 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check total reinvestment intensity of Zhejiang Ausun Pharmaceutical Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Zhejiang Ausun Pharmaceutical Co Ltd - Total Assets Trend (2012–2025)
This chart illustrates how Zhejiang Ausun Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Check Zhejiang Ausun Pharmaceutical Co Ltd (603229) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Zhejiang Ausun Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Zhejiang Ausun Pharmaceutical Co Ltd's total assets of CN¥3.16 Billion consist of 58.8% current assets and 41.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 39.6% |
| Accounts Receivable | CN¥142.03 Million | 4.6% |
| Inventory | CN¥398.30 Million | 12.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥151.56 Million | 4.9% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Zhejiang Ausun Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 603229 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Ausun Pharmaceutical Co Ltd's current assets represent 58.8% of total assets in 2025, an increase from 22.4% in 2012.
- Cash Position: Cash and equivalents constituted 39.6% of total assets in 2025, up from 2.7% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 24.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 12.9% of total assets.
Zhejiang Ausun Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Zhejiang Ausun Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
|
China | CN¥3.25 Billion |
Zhejiang Ausun Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.64 | 2.57 | 2.99 |
| Quick Ratio | 2.12 | 2.03 | 2.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.17 Billion | CN¥1.12 Billion | CN¥670.79 Million |
Zhejiang Ausun Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Zhejiang Ausun Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.55 |
| Latest Market Cap to Assets Ratio | 0.32 |
| Asset Growth Rate (YoY) | 3.4% |
| Total Assets | CN¥3.09 Billion |
| Market Capitalization | $986.57 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Ausun Pharmaceutical Co Ltd's assets below their book value (0.32x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Zhejiang Ausun Pharmaceutical Co Ltd's assets grew by 3.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Zhejiang Ausun Pharmaceutical Co Ltd (2012–2025)
The table below shows the annual total assets of Zhejiang Ausun Pharmaceutical Co Ltd from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.09 Billion ≈ $451.47 Million |
+3.45% |
| 2024-12-31 | CN¥2.98 Billion ≈ $436.42 Million |
+1.04% |
| 2023-12-31 | CN¥2.95 Billion ≈ $431.91 Million |
+27.48% |
| 2022-12-31 | CN¥2.32 Billion ≈ $338.81 Million |
+25.87% |
| 2021-12-31 | CN¥1.84 Billion ≈ $269.17 Million |
+33.13% |
| 2020-12-31 | CN¥1.38 Billion ≈ $202.18 Million |
+55.92% |
| 2019-12-31 | CN¥886.14 Million ≈ $129.67 Million |
+10.49% |
| 2018-12-31 | CN¥801.98 Million ≈ $117.35 Million |
+8.14% |
| 2017-12-31 | CN¥741.58 Million ≈ $108.52 Million |
+66.25% |
| 2016-12-31 | CN¥446.06 Million ≈ $65.27 Million |
+10.99% |
| 2015-12-31 | CN¥401.89 Million ≈ $58.81 Million |
+54.51% |
| 2014-12-31 | CN¥260.11 Million ≈ $38.06 Million |
+45.49% |
| 2013-12-31 | CN¥178.78 Million ≈ $26.16 Million |
+45.86% |
| 2012-12-31 | CN¥122.57 Million ≈ $17.94 Million |
-- |
About Zhejiang Ausun Pharmaceutical Co Ltd
Zhejiang Ausun Pharmaceutical Co., Ltd. engages in the research and development, process development, manufacture, and sale of APIs and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications. In addition, … Read more